CN113121443B - β-氨基酸衍生物、含其之激酶抑制剂与医药组合物以及其用途 - Google Patents
β-氨基酸衍生物、含其之激酶抑制剂与医药组合物以及其用途 Download PDFInfo
- Publication number
- CN113121443B CN113121443B CN202011454931.0A CN202011454931A CN113121443B CN 113121443 B CN113121443 B CN 113121443B CN 202011454931 A CN202011454931 A CN 202011454931A CN 113121443 B CN113121443 B CN 113121443B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- compounds
- kinase
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955683P | 2019-12-31 | 2019-12-31 | |
| US62/955,683 | 2019-12-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113121443A CN113121443A (zh) | 2021-07-16 |
| CN113121443B true CN113121443B (zh) | 2024-07-09 |
Family
ID=74556625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011454931.0A Active CN113121443B (zh) | 2019-12-31 | 2020-12-10 | β-氨基酸衍生物、含其之激酶抑制剂与医药组合物以及其用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11608319B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3845276B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7531379B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN113121443B (cg-RX-API-DMAC10.html) |
| ES (1) | ES3015621T3 (cg-RX-API-DMAC10.html) |
| TW (1) | TWI777325B (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230038697A (ko) * | 2020-07-14 | 2023-03-21 | 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 | Rock 억제제 및 이의 제조 방법과 용도 |
| WO2025143152A1 (ja) | 2023-12-27 | 2025-07-03 | 全薬工業株式会社 | チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| CN101253152A (zh) * | 2005-09-02 | 2008-08-27 | 安斯泰来制药株式会社 | 作为rock抑制剂的酰胺衍生物 |
| US8504218B2 (en) | 2007-07-31 | 2013-08-06 | General Electric Company | Methods and systems for universal input output for vehicle control |
| JP2011507850A (ja) * | 2007-12-21 | 2011-03-10 | ザ スクリプス リサーチ インスティチュート | Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| WO2010126626A2 (en) * | 2009-05-01 | 2010-11-04 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| KR101768235B1 (ko) | 2009-07-28 | 2017-08-14 | 오노 야꾸힝 고교 가부시키가이샤 | 이환식 화합물 및 이의 의약 용도 |
| KR102074020B1 (ko) | 2012-07-13 | 2020-02-05 | 산텐 세이야꾸 가부시키가이샤 | 술폰아미드 화합물의 조합 |
| EP2961746B1 (en) * | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AU2016264220A1 (en) | 2015-05-18 | 2018-01-04 | Translational Drug Development Llc | Heterocyclic compounds as kinase inhibitors |
| JP2019529359A (ja) * | 2016-08-19 | 2019-10-17 | アエリエ ファーマシューティカルズ インコーポレイテッド | ベータ−アミノ−イソキノリニルアミド化合物 |
| WO2018094362A1 (en) * | 2016-11-21 | 2018-05-24 | Translational Drug Development, Llc | Heterocyclic compounds as kinase inhibitors |
| CN111050766A (zh) * | 2017-07-21 | 2020-04-21 | 卡德门企业有限公司 | Rho相关含卷曲螺旋蛋白激酶的抑制剂 |
| US20210087184A1 (en) * | 2018-03-14 | 2021-03-25 | Aerie Pharmaceuticals, Inc. | Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds |
-
2020
- 2020-12-10 CN CN202011454931.0A patent/CN113121443B/zh active Active
- 2020-12-10 JP JP2020204848A patent/JP7531379B2/ja active Active
- 2020-12-10 TW TW109143679A patent/TWI777325B/zh active
- 2020-12-10 EP EP20213242.9A patent/EP3845276B1/en active Active
- 2020-12-10 US US17/117,615 patent/US11608319B2/en active Active
- 2020-12-10 ES ES20213242T patent/ES3015621T3/es active Active
Non-Patent Citations (1)
| Title |
|---|
| 1787986-75-7等;Registry;《STN》;第2-3页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202126628A (zh) | 2021-07-16 |
| JP7531379B2 (ja) | 2024-08-09 |
| EP3845276B1 (en) | 2025-01-29 |
| CN113121443A (zh) | 2021-07-16 |
| TWI777325B (zh) | 2022-09-11 |
| US11608319B2 (en) | 2023-03-21 |
| EP3845276A1 (en) | 2021-07-07 |
| US20220363645A1 (en) | 2022-11-17 |
| JP2021113185A (ja) | 2021-08-05 |
| ES3015621T3 (en) | 2025-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2690748T3 (es) | Derivados de naftiridina como antagonistas de integrina alfa v beta 6 para el tratamiento de enfermedades fibróticas entre otras | |
| ES2289349T3 (es) | Derivados de heteroaril-pirimidina como inhibidores de jak. | |
| ES2384121T3 (es) | Compuestos de N-hidroxiacrilamida | |
| CN104334556B (zh) | 新型1‑磷酸鞘氨醇受体拮抗剂 | |
| AU2019245390B2 (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof | |
| CN103025740B (zh) | 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途 | |
| TWI839375B (zh) | 一氧化氮釋放第５型磷酸二酯酶抑制劑 | |
| WO2012072033A1 (zh) | 取代的2，3-二氮杂萘酮化合物及其用途 | |
| KR20140145203A (ko) | 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체 | |
| TWI777325B (zh) | β-胺基酸衍生物、含其之激酶抑制劑與醫藥組成物以及其用途 | |
| US20170065602A1 (en) | Compounds with trpv4 activity, compositions and associated methods thereof | |
| CN111518028B (zh) | 一种一氧化氮供体型ripasudil衍生物及其制备方法和用途 | |
| KR102758256B1 (ko) | β-아미노산 유도체, 키나아제 억제제 및 이를 함유하는 약학 조성물 | |
| JP7834370B2 (ja) | 緑内障の治療のためのカルパイン－２選択的阻害剤化合物 | |
| CN118339149A (zh) | 用于治疗与lpa受体活性相关的病症的化合物和组合物 | |
| KR20230134547A (ko) | 보호된 hdac(히스톤 디아세틸라제) 억제제 | |
| CN100422161C (zh) | 羟基吗啉酮衍生物及其医药用途 | |
| CN102666563A (zh) | 作为a2a受体激动剂的烷氧基羰基氨基炔基腺苷化合物及其衍生物 | |
| RU2785776C2 (ru) | Ингибитор фосфодиэстеразы 5 типа, высвобождающий оксид азота | |
| HK40120357A (en) | Nitric oxide releasing phosphodiesterase type 5 inhibitor | |
| WO2011140681A1 (zh) | 丙烯酰胺类化合物及其抑制细胞凋亡的用途 | |
| HK40049475B (en) | Nitric oxide releasing phosphodiesterase type 5 inhibitor | |
| HK40049475A (en) | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |